This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Aflibercept or Bevacizumab First for Diabetic Macular Edema

Continue to access content

Select an option below:

This content requires an account.

Create Account

Already have an account?

Sign In

For diabetic macular edema, the relative efficacy of treatment with aflibercept monotherapy as compared with bevacizumab first, with a switch to aflibercept if response is insufficient, is unclear. New research findings are summarized in a short video.

This content requires an NEJM.org account.

Create Account